PinPoint Get PinPoint on the App Store

Peptides / Stack explainer

CJC-1295 and ipamorelin: two secretagogues described one at a time

CJC-1295 and ipamorelin act on two different receptors that both lead to growth hormone release. No combined regimen was studied in the cited sources: ipamorelin's human data come from an intravenous volunteer study, and the human CJC-1295 study used the DAC form alone [3][4]. The cjc 1295 ipamorelin dosage search is therefore answered here as two descriptions, two vial conversions and two records, never as one figure.

PINPOINT EDITORIAL · UPDATED 05 OCT 2026
7 SOURCES · ARITHMETIC SHOWN, NO DOSE ADVICE

Editorial still life from the PinPoint compound library series

ILLUSTRATION / COMPOUND LIBRARY SERIES

What are CJC-1295 and ipamorelin, and what does the pairing mean?

CJC-1295 is an analogue of growth-hormone-releasing hormone, the signal that tells the pituitary to release growth hormone; it exists with and without a drug affinity complex [1]. Ipamorelin is a pentapeptide growth hormone secretagogue that acts through the growth-hormone-releasing peptide receptor, a separate route to the same release [2]. PinPoint's library lists both as limited human research [5].

This explainer uses the library's CJC-1295 entry without DAC for its examples [5]; the DAC form is compared separately in CJC-1295 with DAC vs no DAC. A combined dosage figure would describe neither compound accurately, and no source in the library studied the pair. What can be described is each compound's evidence and each vial's arithmetic.

What do the studies report for CJC-1295 and ipamorelin?

For ipamorelin, a 1999 study infused it intravenously over 15 minutes into healthy men at five ascending rates, eight men per level [3]. Its pharmacokinetics were dose proportional, with a terminal half-life of about two hours. Each infusion produced a single episode of growth hormone release that peaked at about 0.67 hours and then declined to negligible levels at every rate studied.

For CJC-1295, the human pharmacokinetic study in the library used the DAC form, with a half-life of several days [4]. The form without DAC lacks a comparable human study there; its 30-minute input is a low-confidence estimate [5]. The FDA evaluation document is the library's identity source for distinguishing the two forms [1].

Ipamorelin's two-hour library input comes from its volunteer study, while the no-DAC CJC-1295 input does not have that backing [5]. Two names in one search phrase hide that asymmetry. The evidence also differs in route: ipamorelin's numbers come from intravenous infusion, while the library logs both compounds by subcutaneous injection, so even the better-characterised input is carried across a change of route [3][5].

Library records for each compound
CompoundStatusHalf-life inputPackage example
CJC-1295 (no DAC)Limited human research, estimated model data0.5 h5 mg (vendor listing)
IpamorelinLimited human research2 h5 mg (vendor listing)

How are CJC-1295 and ipamorelin vials converted to units?

Both library package examples are 5 mg [5]. In a hypothetical 2 mL each is 2.5 mg/mL, or 2,500 mcg/mL, so each U-100 unit holds 25 mcg and 10 units hold 250 mcg [6]. Because the totals match, the same mark carries the same mass of each, which is a coincidence of these two examples, not a property of the compounds.

A different package size breaks the symmetry immediately: a 2 mg vial in 2 mL would put 10 mcg in each unit. Keeping the vials separate means each can be set up with its own total and volume. The CJC-1295 no-DAC calculator and ipamorelin calculator do this per vial, and the ipamorelin dosing chart prints the columns.

each: 5 mg ÷ 2 mL = 2,500 mcg/mL
1 unit = 0.01 mL = 25 mcg
250 mcg ÷ 2,500 mcg/mL = 0.1 mL = 10 units
CJC-1295 (no DAC) and Ipamorelin: 0.25 mg at the 10-unit mark of each solutionCJC-1295 (no DAC): 5 mg in 2 mL is 2.5 mg per mL, so 0.1 mL holds 0.25 mg. Ipamorelin: 5 mg in 2 mL is 2.5 mg per mL, so 0.1 mL holds 0.25 mg. CJC-1295 (NO DAC) AND IPAMORELIN: 0.25 MG AT THE 10-UNIT MARK OF EACH SOLU CJC-1295 (no DAC): 5 mg ÷ 2 mL = 2.5 mg/mL; 0.1 mL = 0.25 mg U-100 SCALE; MARKED 10 UNITS Ipamorelin: 5 mg ÷ 2 mL = 2.5 mg/mL; 0.1 mL = 0.25 mg U-100 SCALE; MARKED 10 UNITS
Arithmetic illustration from stated inputs. Not a dose or a measured level.

How do people log CJC-1295 and ipamorelin in PinPoint?

Each compound has its own library entry, so two vials and two entries per injection time keep totals and supply forecasts accurate [5][7]. Entries record compound, dose, site and pain level, and site rotation suggests where the next one goes [7].

Once-daily, twice-daily or custom schedules are available with reminders at the chosen times [7]. The Home curve models each from its own input, two hours for ipamorelin and an estimated half hour for no-DAC CJC-1295, as mathematical visualizations that do not account for individual variation [5][7].

Get PinPoint on the App Store

What do people ask about CJC-1295 and ipamorelin?

What is the difference between CJC-1295 and ipamorelin?
CJC-1295 is a growth-hormone-releasing hormone analogue. Ipamorelin is a pentapeptide acting through the growth-hormone-releasing peptide receptor. Both lead to growth hormone release through different receptors.
What is the half-life of ipamorelin?
A 1999 volunteer study reported a terminal half-life of about two hours after intravenous infusion. The library uses two hours as its model input.
How many units is 250 mcg from a 5 mg vial?
In 2 mL the vial holds 2,500 mcg/mL, so 250 mcg is 0.1 mL, or 10 U-100 units. A 1 mL volume would make it 5 units.
Is there a cjc 1295 ipamorelin dosage study?
No study of the pair appears in the library's sources. Ipamorelin has a volunteer pharmacokinetic study, and the human CJC-1295 study used the DAC form alone.
Which CJC-1295 form does this explainer use?
The examples use the library's CJC-1295 entry without DAC, which has a 30-minute low-confidence input. The DAC form has an eight-day input and is compared in a separate explainer. Neither form was studied together with ipamorelin in the cited sources.

Where do these facts come from?

Sources are listed by kind: labels first, then peer-reviewed papers, then PinPoint's own library, arithmetic and app description. Library values were retrieved from the PinPoint application on 5 October 2026; vendor listings support package sizes only.

  1. FDA evaluation document for CJC-1295FDA document identifying CJC-1295 forms with and without the drug affinity complex.Retrieved 2026-10-05 · regulatory-review
  2. Ipamorelin, the first selective growth hormone secretagogue, 1998Endocrinology journal, 1998. Identifies ipamorelin as a pentapeptide acting through a growth-hormone-releasing peptide receptor; rat and swine pharmacology.Retrieved 2026-10-05 · study
  3. Pharmacokinetic and pharmacodynamic modeling of ipamorelin in volunteers, 1999Pharm Res, 1999. Intravenous infusion in healthy adults.Retrieved 2026-10-05 · study
  4. Prolonged GH and IGF-I secretion after CJC-1295 in healthy adults, 2006J Clin Endocrinol Metab, 2006. Single and multiple subcutaneous doses; half-life of several days.Retrieved 2026-10-05 · study
  5. PinPoint compound library, application recordsHalf-life inputs, routes, frequencies, package examples and confidence labels as stored in the iOS app library and mirrored in the peptide guides.Retrieved 2026-10-05 · library
  6. Unit conversion arithmeticConcentration = amount / volume; volume = amount / concentration; U-100 units = mL x 100; remaining fraction = 2^(-elapsed / half-life).Retrieved 2026-10-05 · arithmetic
  7. PinPoint App Store descriptionFeature wording from the approved application description, not pricing.Retrieved 2026-10-05 · app-description